Smallpox Vaccines

Preclinical studies provide safety and efficacy evidence for smallpox vaccine candidate

Published in Vaccine Weekly, December 28th, 2005

Data from a series of preclinical studies presented by the Chemo-Sero Therapeutic Research Institute (Kaketsuken) at the 53rd Annual Conference of the Japanese Society of Virology provided additional evidence of the safety and efficacy of an attenuated smallpox vaccine being developed by VaxGen, Inc. (VXGN.PK).

The attenuation refers to a genetic modification that is intended to improve the vaccine's safety.

The purpose of the studies was to compare the safety of VaxGen's attenuated vaccine candidate, LC16m8, with that of the unattenuated Lister strain of vaccinia. Lister vaccine, the parent strain from which LC16m8 is derived, was used in the World...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Vaccine Weekly

Source: Vaccine Weekly (2005-12-28)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry